SPL UNCLASSIFIED SECTION
Homeopathic Analgesic Medicine
5 CAPSULES
Homeopathic Analgesic Medicine
5 CAPSULES
For temporary pain relief of swollen lymph glands.
1 capsule contains 330 mg Bacillus subtilis 4X in a base of lactose.
Capsule shells consist of Hypromellose (HPMC).
1–2 capsules weekly, one capsule either before breakfast or at bedtime.
If symptoms persist more than a few days, contact a licensed practitioner. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before taking this product. Keep this and all medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately. Protect from light and heat.
Do not use this product if shrink-wrap is missing from the carton or the imprinted blister foil is broken.
Made in Germany.
Distributed by:
SANUM USA Corp.
1465 Slater Road
Ferndale, WA 98248
Manufactured by:
Sanum-Kehlbeck
GmbH & Co. KG
Rev. 12/2004
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60681-5302-2 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-d40a-621f-e053-dbdaa90a74ad | Pleo™ Ut CAPSULES 4X |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60681-5302-2 | Pleo Ut | 5 in 1 BLISTER PACK | CAPSULE | 5 | 1 | |
| 60681-5302-2 | Pleo Ut | 1 in 1 CARTON | CAPSULE | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60681-5302 | PLEO UT (BACILLUS SUBTILIS) CAPSULE [SANUM KEHLBECK GMBH & CO. KG] | 1 | Legacy NDC, 2 package rows | 20110113_01ca3cf1-e284-4699-bc3f-3d18bcd4c5ef.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| bacillus subtilis | ACTIVE INGREDIENT | 8CF93KW41W | 1 | |
| bacillus subtilis | ACTIVE MOIETY | 8CF93KW41W | 1 | |
| hypromellose | INACTIVE INGREDIENT | 3NXW29V3WO | 1 | |
| lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60681-5302 | 60681-5302-2 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| bacillus subtilis | 8CF93KW41W | ACTIB |
| lactose | J2B2A4N98G | IACT |
| hypromellose | 3NXW29V3WO | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED PELLETS / ORAL | 3.32 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, DELAYED RELEASE / ORAL | 79 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SYRUP / ORAL | 250 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | LOTION / TOPICAL | 0.1 %w/w | ||
| lactose | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SYSTEM / TOPICAL | 54 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GRANULE / ORAL | 45 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, EXTENDED RELEASE / ORAL | 119.7 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SHAMPOO / TOPICAL | 3 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 221 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / ORAL | 305 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, ORALLY DISINTEGRATING / ORAL | 41 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GRANULE, FOR SUSPENSION / ORAL | 1.7 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE / ORAL | 1488 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CREAM / TOPICAL | 0.1 %w/w | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / OPHTHALMIC | 0.5 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, CHEWABLE / ORAL | 11.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, EXTENDED RELEASE / ORAL | 1472 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, DELAYED RELEASE / ORAL | 105 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | JELLY / TOPICAL | NA | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GEL / RECTAL | 348 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 8c87f0eb-b4a4-4ae4-965e-07b2280907d9 | 01ca3cf1-e284-4699-bc3f-3d18bcd4c5ef | 2009-10-08 | Warnings | 8c87f0eb-b4a4-4ae4-965e-07b2280907d9 01ca3cf1-e284-4699-bc3f-3d18bcd4c5ef |
Adverse event summaries are temporarily unavailable. Other product information remains available.